Pfizer Inc. (PFE) Social Stream

Pfizer Inc. (PFE): $39.19

0.14 (+0.36%)

POWR Rating

Component Grades













Featured Post From StockTwits About PFE

$OCGN So now the virus has chosen innocent young people. No more infecting older as they are almost all vaccinated. Very intelligent virus I must say.
$PFE and $MRNA and $AZN thanks big pharma and Fauci hiding your info since 2011 and pretending you knew nothing about it.
So, before Covid was attacking older and vulnerable. Now as it mutated, only children are at risk so they have to vaccinate all of them. It doesn't matter that it has been reported that children getting heart inflammation.
Invest in Ocugen, at least you have a choice.
Tomasso, published June 17, 2021

What Else are PFE Traders Talking About?

Other tickers frequently mentioned alongside PFE are OCGN, MRNA, AZN and CALA.

Other Notable StockTweets About PFE

$PFE Bounced off the Upper Bollinger last month, retraced to its 50SMA where I added some additional shares. $PFE now on the rise with key resistance levels at 20SMA $39.56 and Upper Bollinger 40.56, respectively. RSI at 52, and the MACD (Bearish) is starting to turn. $PFE beat revenue and EPS estimates for Q1, but they improved their forecast for 2021 substantially. Everyone knows about the success of its COVID vaccine, but Pfizer hit an 8% CAGR on all non-COVID vaccine product lines (target 6%), which shows the growing strength of its broader portfolio. Again-strong revenue growth both COVID and non, balanced capital structure, good liquidity, Net Margin of 20% (Industry 16) and now trading at a P/E of 10.8.

BinaryLogic, published June 5, 2021

$CALA There r 2 types of NSCLC. The wild type and those w/ the NRF2/KEAP1 mutation. The more common is wild type which makes for 80% of cases. These patients have ~3.5 months to live if untreated. When getting SOC they get another ~6 months. For the 20% that have NRF2/KEAP1 mutation they also have 3.5 months to live untreated, however they do not benefit from SOC & get NO extended survival time. The KEAPSAKE trial is comprised of NSCLC patients with only the NRF2/KEAP1 mutation. If successful, CALA will be the sole player in a very lucrative $10B annual treatment market for at least 2 years. $5B in sales w/ margins in excess of 50% will generate $2.5B in profits for CALA annually. 10X earnings will value CALA at $25B or $250.00 p/s. This assigns ZERO value to 1158 or CALA's partnership w/ $INCY, ZERO value to CALA's expanding collab with $PFE, ZERO value to CD73 and the prtnrshp with Antengene, ZERO value to CALA's IL4I1 Inhibitor and ZERO value to CALA's Cystic Fibrosis (280) program.

CaptainFancyPantz, published June 1, 2021

Loading social stream, please wait...

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7164 seconds.